Liquidia Technologies Inc 的股价今晨暴涨近 30%，此前该公司与竞争对手美国联合医疗达成和解，终结了六起诉讼。这场持续多年的法律战一度威胁到 Liquidia 主打药物 Yutrepia 的销售前景。总部位于北卡罗来纳州莫里斯维尔的 Liquidia 表示，将在 2027 年前向美国联合医疗支付约 3.8 亿美元。Yutrepia 是一款吸入式肺部药物，将继续用于治疗肺动脉高压——一种会导致肺部动脉变窄的疾病。今年 9 月，一名法官裁定 Liquidia 侵犯了美国联合医疗的一项专利，该专利涉及 Yutrepia 活性成分用于治疗另一种肺部疾病的用途。当日 Liquidia 股价暴跌 57%。作为和解协议的一部分，Liquidia 同意不上诉，并表示将停止针对该适应症推广 Yutrepia。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.